AnaptysBio Stock Drops Despite Massive Q2 Earnings Beat as GSK Court Ruling Looms

AnaptysBio Inc. (NASDAQ: ANAB) reported a substantial second-quarter earnings and revenue beat on September 22, but its shares fell in a classic "beat-and-drop" reaction from the market. The company's strong performance was overshadowed by investor uncertainty surrounding a pending court ruling involving its key royalty partner, GSK plc.

Strong Results Validate Royalty Model

AnaptysBio announced a second-quarter EPS of $5.11, massively surpassing the consensus estimate of a $0.13 loss per share. Revenue for the quarter came in at $27.5 million, beating expectations of $20.22 million by over 36%, according to the company's Q2 FY2026 report.

The positive results were driven by higher-than-expected royalty revenue from the GSK-partnered cancer drug Jemperli. This performance validates the company's capital-efficient "virtual royalty model" and confirms that a weak first quarter, impacted by a spinoff, was a transitional issue.

Market Focus Shifts to Litigation

Despite the strong financial report, AnaptysBio's stock was trading down approximately 5.6% in afternoon trading. The negative market reaction appears tied to the absence of news regarding a breach of contract trial with GSK/Tesaro that concluded in July.

Ad

Investors had anticipated a ruling, with a favorable outcome potentially leading to a litigation windfall or even a reversion of Jemperli's rights to AnaptysBio. With no announcement, the market is pricing out that near-term upside. Additionally, the company's revenue is structurally capped until a royalty monetization agreement with Sagard concludes between mid-2027 and mid-2028.

Key Catalysts on the Horizon

Investors are now watching several upcoming milestones that could significantly impact the company's valuation. The timing and outcome of these events will be critical for AnaptysBio's trajectory.

• Delaware Court Ruling: A pending decision on the GSK breach of contract trial represents the most significant potential catalyst.
• Imsidolimab FDA Decision: The FDA's decision on imsidolimab for generalized pustular psoriasis (GPP) is expected by December 12, 2026, potentially adding a second royalty stream via partner Vanda Pharmaceuticals.
• Jemperli PDUFA Date: An FDA priority review for Jemperli in a new rectal cancer indication has a target action date in February 2027.
• Sagard Agreement Payoff: The conclusion of the royalty monetization agreement in mid-2027 to mid-2028 will allow AnaptysBio to capture the full royalty stream from its assets.